{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.3","value":"38.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"}],"units":"Participants"}],"title":"C2D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.6","value":"74.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.2","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.6","value":"119.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"C13D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.5","value":"147.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"C17D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"}],"units":"Participants"}],"description":"Ctrough was defined as the predose concentration at the end of dosing interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21","id":"OG000","title":"CAPOX+ Zolbetuximab"}],"paramType":"MEAN","populationDescription":"Pharmakokinetic analysis set (PKAS) consisted of the subset of the SAF for which at least 1 zolbetuximab concentration measurement was available. Participants with available data at each timepoint were analyzed.","reportingStatus":"POSTED","timeFrame":"Predose on C2D1,C5D1,C9D1,C13D1,C17D1","title":"Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)","type":"SECONDARY","unitOfMeasure":"micrograms/mililiter (ug/mL)"}